Killa Acne Extra Strength

Description

Killa Acne ES PDP is presented in a four-pack format, identified as KAES 4 Pack PDP. The effective date of this product is April 6, 2023. The observation media associated with this product is an image in JPEG format, referenced as KAES 4 Pack PDP.jpg.

Uses and Indications

This drug is indicated for the management of acne. It penetrates pores to eliminate most blemishes effectively.

Limitations of Use: There are no teratogenic or nonteratogenic effects mentioned associated with this drug.

Dosage and Administration

No dosage and administration information is available in the provided text.

Contraindications

Use of this product is contraindicated in patients who are concurrently using another topical acne medication. The combination may lead to increased skin irritation and dryness. If irritation occurs, it is advised to use only one topical acne medication at a time unless directed by a healthcare professional.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to avoid ingestion of the product. In the event of accidental swallowing, it is imperative to seek emergency medical assistance or contact a Poison Control Center immediately.

Patients should be instructed to discontinue use and consult their healthcare provider if they experience severe irritation. Monitoring for signs of irritation is essential to ensure patient safety and to determine the need for further medical evaluation.

Side Effects

Patients should be advised that the product is for external use only. In clinical practice, if irritation becomes severe, it is recommended that the use of the product be discontinued immediately. Monitoring for adverse reactions is essential to ensure patient safety and to address any potential complications that may arise from the use of the product.

Drug Interactions

Concurrent use of topical acne medications may lead to skin irritation and dryness. It is advisable to avoid the simultaneous application of multiple topical acne treatments or the use of another topical acne medication immediately following the application of the first. In cases where irritation occurs, it is recommended to limit the use to one topical acne medication at a time unless otherwise directed by a healthcare professional. Monitoring for signs of skin irritation is suggested to ensure patient comfort and treatment efficacy.

Packaging & NDC

Below are the non-prescription pack sizes of Killa Acne Extra Strength (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population, given the lack of targeted data.

Pregnancy

There is no specific information available regarding the use of this drug during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. It is advisable to weigh the potential benefits against any unknown risks to fetal outcomes. Women of childbearing potential should be counseled on the importance of effective contraception during treatment and the need to inform their healthcare provider if they become pregnant or plan to become pregnant while using this medication.

Lactation

Nursing mothers should consult a healthcare professional before using this product. There is a potential for excretion in breast milk; therefore, caution is advised when using this product while breastfeeding. The effects on a nursing infant are not well studied; thus, the risks versus benefits should be considered.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to consult local poison control centers or relevant toxicology resources for guidance on specific management protocols and antidotes, if applicable.

Documentation of the incident, including the substance involved, estimated dose, and time of exposure, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the medication is swallowed. It is crucial for patients to understand the potential risks associated with accidental ingestion.

Patients should be informed that skin irritation and dryness may occur if they use this medication concurrently with another topical acne treatment or immediately afterward. It is recommended that patients use only one topical acne medication at a time unless otherwise directed by a healthcare professional.

In the event that skin irritation becomes severe, patients should be instructed to discontinue use of the medication and consult their healthcare provider for further guidance.

Storage and Handling

The product is supplied in a configuration that ensures optimal usability. It should be stored at room temperature to maintain its integrity and effectiveness. It is essential to keep the product out of reach of children to prevent accidental ingestion. Once opened, the product must be discarded to ensure safety and efficacy.

Additional Clinical Information

The product is administered topically. Clinicians should advise patients that if severe irritation occurs, they should consult a doctor. Patients may experience skin irritation and dryness, particularly if using another topical acne medication concurrently or immediately after application. It is recommended that only one topical acne medication be used at a time unless otherwise directed by a healthcare professional.

Additionally, patients should be instructed to keep the product out of reach of children. In the event of accidental ingestion, immediate medical assistance or contact with a Poison Control Center is necessary.

Drug Information (PDF)

This file contains official product information for Killa Acne Extra Strength, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)